We served as lead regulatory counsel to a private equity investment firm in its multi-billion dollar bid to take a publicly traded healthcare company private. Our team conducted regulatory due diligence and advised the private equity investment firm on the deal.
Private Equity Firm Takes Public Company Private
You Also May Be Interested In:
We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc., emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.
Served as lead counsel to BriovaRx Infusion Services in obtaining a Certificate of Need to expand services in Middle Tennessee